company background image
AZN

AstraZenecaLSE:AZN Stock Report

Market Cap

UK£128.2b

7D

-2.4%

1Y

6.1%

Updated

30 Nov, 2021

Data

Company Financials +
AZN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends4/6

AZN Stock Overview

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide.

AstraZeneca Competitors

GlaxoSmithKline

LSE:GSK

UK£76.4b

Indivior

LSE:INDV

UK£1.6b

Johnson & Johnson

NYSE:JNJ

US$410.5b

Roche Holding

SWX:ROG

CHF310.8b

Price History & Performance

Summary of all time highs, changes and price drops for AstraZeneca
Historical stock prices
Current Share PriceUK£82.76
52 Week HighUK£95.23
52 Week LowUK£67.36
Beta0.15
1 Month Change-9.00%
3 Month Change-2.82%
1 Year Change6.10%
3 Year Change33.25%
5 Year Change104.98%
Change since IPO1,146.39%

Recent News & Updates

Sep 27
Is AstraZeneca (LON:AZN) Using Too Much Debt?

Is AstraZeneca (LON:AZN) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

AZNGB PharmaceuticalsGB Market
7D-2.4%-1.6%-2.6%
1Y6.1%8.4%10.9%

Return vs Industry: AZN underperformed the UK Pharmaceuticals industry which returned 9.2% over the past year.

Return vs Market: AZN underperformed the UK Market which returned 13.8% over the past year.

Price Volatility

Is AZN's price volatile compared to industry and market?
AZN volatility
AZN Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: AZN is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: AZN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199276,100Pascal Soriothttps://www.astrazeneca.com

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca.

AstraZeneca Fundamentals Summary

How do AstraZeneca's earnings and revenue compare to its market cap?
AZN fundamental statistics
Market CapUS$169.75b
Earnings (TTM)US$1.47b
Revenue (TTM)US$32.82b

115.4x

P/E Ratio

5.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AZN income statement (TTM)
RevenueUS$32.82b
Cost of RevenueUS$9.06b
Gross ProfitUS$23.75b
ExpensesUS$22.28b
EarningsUS$1.47b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 10, 2022

Earnings per share (EPS)0.95
Gross Margin72.38%
Net Profit Margin4.48%
Debt/Equity Ratio83.7%

How did AZN perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

342%

Payout Ratio

Valuation

Is AstraZeneca undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AZN (£82.76) is trading below our estimate of fair value (£193.07)

Significantly Below Fair Value: AZN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AZN is poor value based on its PE Ratio (115.4x) compared to the UK Pharmaceuticals industry average (29.7x).

PE vs Market: AZN is poor value based on its PE Ratio (115.4x) compared to the UK market (19x).


Price to Earnings Growth Ratio

PEG Ratio: AZN is poor value based on its PEG Ratio (3.7x)


Price to Book Ratio

PB vs Industry: AZN is good value based on its PB Ratio (4.3x) compared to the GB Pharmaceuticals industry average (4.5x).


Future Growth

How is AstraZeneca forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?

31.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZN's forecast earnings growth (31.6% per year) is above the savings rate (0.9%).

Earnings vs Market: AZN's earnings (31.6% per year) are forecast to grow faster than the UK market (12.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AZN's revenue (10.4% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: AZN's revenue (10.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AZN's Return on Equity is forecast to be very high in 3 years time (68.8%).


Past Performance

How has AstraZeneca performed over the past 5 years?

-5.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AZN has a large one-off loss of $417.0M impacting its September 30 2021 financial results.

Growing Profit Margin: AZN's current net profit margins (4.5%) are lower than last year (9.7%).


Past Earnings Growth Analysis

Earnings Trend: AZN's earnings have declined by 5.4% per year over the past 5 years.

Accelerating Growth: AZN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AZN had negative earnings growth (-41.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-20.6%).


Return on Equity

High ROE: AZN's Return on Equity (3.7%) is considered low.


Financial Health

How is AstraZeneca's financial position?


Financial Position Analysis

Short Term Liabilities: AZN's short term assets ($26.7B) exceed its short term liabilities ($23.6B).

Long Term Liabilities: AZN's short term assets ($26.7B) do not cover its long term liabilities ($43.7B).


Debt to Equity History and Analysis

Debt Level: AZN's net debt to equity ratio (65.8%) is considered high.

Reducing Debt: AZN's debt to equity ratio has reduced from 118.1% to 83.7% over the past 5 years.

Debt Coverage: AZN's debt is not well covered by operating cash flow (19%).

Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (4.7x coverage).


Balance Sheet


Dividend

What is AstraZeneca current dividend yield, its reliability and sustainability?

2.56%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: AZN's dividend (2.56%) is higher than the bottom 25% of dividend payers in the UK market (1.37%).

High Dividend: AZN's dividend (2.56%) is low compared to the top 25% of dividend payers in the UK market (4.17%).


Stability and Growth of Payments

Stable Dividend: AZN's dividends per share have been stable in the past 10 years.

Growing Dividend: AZN's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (341.7%), AZN's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: AZN's dividends in 3 years are forecast to be well covered by earnings (34.4% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.8yrs

Average management tenure


CEO

Pascal Soriot (62 yo)

9.08yrs

Tenure

US$21,089,782

Compensation

Mr. Pascal Soriot, M.B.A., D.V.M., serves as Director at Acerta Pharma B.V. He joined Acerta Pharma in January 2018 as Vice President Research Europe & Site Head of Acerta’s R&D site in The Netherlands. Dr...


CEO Compensation Analysis

Compensation vs Market: Pascal's total compensation ($USD21.09M) is above average for companies of similar size in the UK market ($USD3.65M).

Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AZN's management team is seasoned and experienced (8.8 years average tenure).


Board Members

Experienced Board: AZN's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.


Top Shareholders

Company Information

AstraZeneca PLC's employee growth, exchange listings and data sources


Key Information

  • Name: AstraZeneca PLC
  • Ticker: AZN
  • Exchange: LSE
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£128.207b
  • Shares outstanding: 1.55b
  • Website: https://www.astrazeneca.com

Number of Employees


Location

  • AstraZeneca PLC
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge
  • Cambridgeshire
  • CB2 0AA
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 21:35
End of Day Share Price2021/11/30 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.